List Title | APhA DrugInfoLine

Focus on Anticoagulation Care

SORT BY: Most Recent Most Viewed

September 11, 2018

Apixaban is an option for anticoagulation in patients on dialysis

READ

PREVIEW
Use of standard-dose apixaban (Eliquis—Bristol-Myers Squibb, Pfizer) in patients with atrial fibrillation (AF) and end-stage renal disease (ESRD) who are on dialysis was associated with a...
August 21, 2018

Real-world outcomes of direct oral anticoagulants versus warfarin

READ

PREVIEW
Apixaban (Eliquis—Bristol-Myers Squibb, Pfizer) appeared to be the safest direct oral anticoagulant compared with warfarin with respect to major, intracranial, and gastrointestinal bleeding,...
April 10, 2018

New oral option for cancer-associated VTE

READ

PREVIEW
Use of long-term oral edoxaban (Savaysa—Daiichi-Sankyo) in patients with cancer and an acute venous thromboembolism (VTE) was found to be noninferior to long-term use of subcutaneous dalteparin...
March 13, 2018

Mortality varies in patients with intracerebral hemorrhage using different anticoagulants

READ

PREVIEW
In-hospital mortality after an intracerebral hemorrhage was lower in patients with prior use of non-vitamin K antagonist oral anticoagulants (NOACs) compared with those who used warfarin...
February 12, 2018

New decision pathway for managing bleeding in patients on oral anticoagulants

READ

PREVIEW
An expert consensus decision pathway on management of bleeding in patients on oral anticoagulants (i.e., vitamin K antagonists [VKA] or the newer direct oral anticoagulants [NOAC]) was released by...

Pages

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.